NCT01153815View on ClinicalTrials.gov

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity

PHASE3CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Cerebrovascular Accident
Interventions
DRUG

GSK1358820(Botulinum toxin type A)

"GSK1358820 (Botulinum Toxin Type A, also known as OnabotulinumtoxinA or Botox)"

DRUG

placebo

placebo

Trial Locations (13)

100050

GSK Investigational Site, Beijing

100068

GSK Investigational Site, Beijing

100730

GSK Investigational Site, Beijing

110001

GSK Investigational Site, Shenyang

150001

GSK Investigational Site, Haerbin

200025

GSK Investigational Site, Shanghai

200040

GSK Investigational Site, Shanghai

210029

GSK Investigational Site, Nanjing

215004

GSK Investigational Site, Suzhou

310016

GSK Investigational Site, Hangzhou

430060

GSK Investigational Site, Wuhan

610041

GSK Investigational Site, Chengdu

Unknown

GSK Investigational Site, Guangzhou

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01153815 - A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity | Biotech Hunter | Biotech Hunter